Corpus Intelligence IC Memo — BANNER DESERT MEDICAL CENTER 2026-04-26 04:02 UTC
IC Memo — BANNER DESERT MEDICAL CENTER
Investment Committee Memorandum | AZ | 629 beds | Grade C | EBITDA uplift $61.3M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

BANNER DESERT MEDICAL CENTER

CCN 030065 | MARICOPA, AZ | 629 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

BANNER DESERT MEDICAL CENTER is a 629-bed safety-net/medicaid heavy in MARICOPA, AZ with $833.1M in net patient revenue and a 12.6% operating margin. The hospital serves a payer mix of 14.2% Medicare, 37.6% Medicaid, and 48.2% commercial.

Thesis: Platform Growth. Our ML models identify $61.3M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 12.6% to 20.0% (+736bps).

Net Revenue HCRIS$833.1M
Current EBITDA COMPUTED$105.4M
Operating Margin COMPUTED12.6%
Occupancy HCRIS72.9%
Revenue / Bed COMPUTED$1.3M
Net-to-Gross HCRIS23.6%
Distress Probability ML51.5%

2. Market Context & Competitive Position

124
AZ Hospitals
-0.8%
State Median Margin
16
Comparable Hospitals

AZ has 124 Medicare-certified hospitals with a median operating margin of -0.8%. The target's margin of 12.6% places it above the state median. Among 16 size-comparable peers (314-1258 beds), the median margin is -1.7%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (314-1258), prioritizing same-state peers. 16 hospitals in the comp set.

HospitalStateBedsRevenueMargin
BANNER DESERT MEDICAL CENTER (Target)AZ629$833.1M12.6%
MAYO CLINIC HOSPITALAZ315$2.25B1.4%
BANNER ESTRELLA MEDICAL CENTERAZ317$1.84B79.2%
BANNER BAYWOOD MEDICAL CENTERAZ323$1.39B79.1%
ST. JOSEPHS HOSPITAL & MEDICALAZ515$1.31B-17.7%
PHOENIX CHILDRENS HOSPITALAZ352$1.26B6.0%
BANNER UNIVERSITY MEDICAL CENTAZ656$1.09B-5.9%
BANNER UNIVERSITY MED CENTER TAZ533$1.03B-4.6%
TUCSON MEDICAL CENTERAZ499$747.4M-2.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $61.3M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$17.5M+210bp18mo
Cost to Collect4.5%2.5%$16.7M+200bp12mo
Denial Rate Reduction12.0%6.5%$16.5M+198bp12mo
A/R Days Reduction5200.0%3800.0%$10.1M+122bp9mo
Clean Claim Rate88.0%96.0%$533K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$17.5M
Cost to Collect
$16.7M
Denial Rate Reduction
$16.5M
A/R Days Reduction
$10.1M
Clean Claim Rate
$533K
Total EBITDA Uplift$61.3M
Current EBITDA$105.4M
+ RCM Uplift+$61.3M
Pro Forma EBITDA$166.7M
Current Margin12.6%
Pro Forma Margin20.0%
WC Released (1x)$32.0M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$162.1M$1.31B8.07x51.8%
Base (11x exit)10.0x11.0x$162.1M$1.49B9.20x55.9%
Bull Case9.0x11.0x$145.9M$1.75B11.97x64.3%
Bull (12x exit)9.0x12.0x$145.9M$1.95B13.36x67.9%
Bear Case11.0x10.0x$178.3M$949.0M5.32x39.7%
Bear (11x exit)11.0x11.0x$178.3M$1.10B6.18x43.9%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumElevated Medicaid exposure (37.6%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 51.5% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 16 hospitals with 314-1258 beds
  • Same-state prioritization (n=17)
  • Comp margins: P25=-4.9% / P50=-1.7% / P75=6.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.